Jiong Luo

Beijing Key Laboratory Of Mental Disorders
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Reduced suicidality after electroconvulsive therapy is linked to increased frontal brain activity in depressed patients: a resting-state fMRI study.

Reduced suicidality after electroconvulsive therapy is linked to increased frontal brain activity in depressed patients: a resting-state fMRI study.

Journal: Frontiers in psychiatry

Published: May 18, 2023

Abnormal fiber integrity in the cerebellum with recent suicide behavior in depressed patients: A diffusion tensor imaging study.

Abnormal fiber integrity in the cerebellum with recent suicide behavior in depressed patients: A diffusion tensor imaging study.

Journal: Asian journal of psychiatry

Published: March 22, 2023

A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.

A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.

Journal: Translational psychiatry

Published: October 18, 2022

Cardiovascular Effects of High-Frequency Magnetic Seizure Therapy Compared With Electroconvulsive Therapy.

Cardiovascular Effects of High-Frequency Magnetic Seizure Therapy Compared With Electroconvulsive Therapy.

Journal: The journal of ECT

Published: February 27, 2022

Relationship of free thyroxine and triiodothyronine on recurrence in maintenance therapy for bipolar depression.

Relationship of free thyroxine and triiodothyronine on recurrence in maintenance therapy for bipolar depression.

Journal: Asian journal of psychiatry

Published: November 17, 2021

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.

Journal: The international journal of neuropsychopharmacology

Published: August 11, 2021

Shorter recovery times and better cognitive function-A comparative pilot study of magnetic seizure therapy and electroconvulsive therapy in patients with depressive episodes.

Shorter recovery times and better cognitive function-A comparative pilot study of magnetic seizure therapy and electroconvulsive therapy in patients with depressive episodes.

Journal: Brain and behavior

Published: June 30, 2020

Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial.

Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial.

Journal: Bipolar disorders

Published: March 27, 2018

Perception of inpatients following remission of a manic episode in bipolar I disorder on a group-based Psychoeducation program: a qualitative study.

Perception of inpatients following remission of a manic episode in bipolar I disorder on a group-based Psychoeducation program: a qualitative study.

Journal: BMC psychiatry

Published: September 10, 2017

Retrospective analysis of factors associated with quetiapine dosage in the acute and subsequent six-month maintenance treatment of bipolar disorders.

Retrospective analysis of factors associated with quetiapine dosage in the acute and subsequent six-month maintenance treatment of bipolar disorders.

Journal: Neuropsychiatric disease and treatment

Published: May 08, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026